Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT ID: NCT00710580
Last Updated: 2013-01-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
350 participants
INTERVENTIONAL
2008-07-31
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00691964
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00570986
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
NCT00679731
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00292396
Open Label Continuation Study in Moderate to Severe Psoriasis
NCT00626002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
ABT-874
SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
B
etanercept
SQ injection 50 mg BIW
C
placebo
SQ placebo injections for ABT-874 and etanercept
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-874
SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
etanercept
SQ injection 50 mg BIW
placebo
SQ placebo injections for ABT-874 and etanercept
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BSA 10%
* PASI 12 or above
* PGA 3 or above
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paragon Biomedical
INDUSTRY
AbbVie (prior sponsor, Abbott)
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Kaul, MD
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 9984
Birmingham, Alabama, United States
Site Reference ID/Investigator# 10605
Birmingham, Alabama, United States
Site Reference ID/Investigator# 10001
Scottsdale, Arizona, United States
Site Reference ID/Investigator# 10502
Little Rock, Arkansas, United States
Site Reference ID/Investigator# 9985
Bakersfield, California, United States
Site Reference ID/Investigator# 10661
Irvine, California, United States
Site Reference ID/Investigator# 14701
Los Angeles, California, United States
Site Reference ID/Investigator# 9785
San Diego, California, United States
Site Reference ID/Investigator# 10662
Santa Monica, California, United States
Site Reference ID/Investigator# 10642
Vallejo, California, United States
Site Reference ID/Investigator# 10263
New Haven, Connecticut, United States
Site Reference ID/Investigator# 10503
Jacksonville, Florida, United States
Site Reference ID/Investigator# 10266
Miami, Florida, United States
Site Reference ID/Investigator# 9901
Miami, Florida, United States
Site Reference ID/Investigator# 10501
West Palm Beach, Florida, United States
Site Reference ID/Investigator# 15201
Alpharetta, Georgia, United States
Site Reference ID/Investigator# 10762
Atlanta, Georgia, United States
Site Reference ID/Investigator# 10262
Newnan, Georgia, United States
Site Reference ID/Investigator# 9789
Snellville, Georgia, United States
Site Reference ID/Investigator# 10666
Maywood, Illinois, United States
Site Reference ID/Investigator# 15142
Plainfield, Indiana, United States
Site Reference ID/Investigator# 10265
Louisville, Kentucky, United States
Site Reference ID/Investigator# 15750
Owensboro, Kentucky, United States
Site Reference ID/Investigator# 9790
Owensboro, Kentucky, United States
Site Reference ID/Investigator# 9788
Fort Gratiot, Michigan, United States
Site Reference ID/Investigator# 10604
Grand Blanc, Michigan, United States
Site Reference ID/Investigator# 10541
Fridley, Minnesota, United States
Site Reference ID/Investigator# 10641
St Louis, Missouri, United States
Site Reference ID/Investigator# 10606
Omaha, Nebraska, United States
Site Reference ID/Investigator# 10644
Omaha, Nebraska, United States
Site Reference ID/Investigator# 9786
Berlin, New Jersey, United States
Site Reference ID/Investigator# 10241
New York, New York, United States
Site Reference ID/Investigator# 9787
Rochester, New York, United States
Site Reference ID/Investigator# 9902
Hickory, North Carolina, United States
Site Reference ID/Investigator# 10581
Wilmington, North Carolina, United States
Site Reference ID/Investigator# 10504
Dayton, Ohio, United States
Site Reference ID/Investigator# 10643
Knoxville, Tennessee, United States
Site Reference ID/Investigator# 9981
Dallas, Texas, United States
Site Reference ID/Investigator# 10264
San Antonio, Texas, United States
Site Reference ID/Investigator# 9982
Webster, Texas, United States
Site Reference ID/Investigator# 10182
Seattle, Washington, United States
Site Reference ID/Investigator# 10321
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Strober BE, Crowley JJ, Yamauchi PS, Olds M, Williams DA. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol. 2011 Sep;165(3):661-8. doi: 10.1111/j.1365-2133.2011.10419.x. Epub 2011 Jul 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M10-315
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.